Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread

(a) Coronavirus disease 2019 (COVID-19) Situation Report – 38. 2019. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200227-sitrep-38-covid-19.pdf?sfvrsn=9f98940c_2;
(b) Zheng, J SARS-CoV-2: An emerging coronavirus that causes a global threat. Int. J. Biol. Sci, 2020, 16(10), 1678-1685.
[http://dx.doi.org/10.7150/ijbs.45053] [PMID: 32226285]

Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A.C.K.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol., 2016, 24(6), 490-502.
[http://dx.doi.org/10.1016/j.tim.2016.03.003] [PMID: 27012512]

Zhong, N.S.; Zheng, B.J.; Li, Y.M.; Poon, L.L.M.; Xie, Z.H.; Chan, K.H.; Li, P.H.; Tan, S.Y.; Chang, Q.; Xie, J.P.; Liu, X.Q.; Xu, J.; Li, D.X.; Yuen, K.Y.; Peiris, J.S.M.; Guan, Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet, 2003, 362(9393), 1353-1358.
[http://dx.doi.org/10.1016/S0140-6736(03)14630-2] [PMID: 14585636]

Drosten, C.; Günther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R.A.M.; Berger, A.; Burguière, A.M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J.C.; Müller, S.; Rickerts, V.; Stürmer, M.; Vieth, S.; Klenk, H.D.; Osterhaus, A.D.M.E.; Schmitz, H.; Doerr, H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med., 2003, 348(20), 1967-1976.
[http://dx.doi.org/10.1056/NEJMoa030747] [PMID: 12690091]

Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W.; Rollin, P.E.; Dowell, S.F.; Ling, A.E.; Humphrey, C.D.; Shieh, W.J.; Guarner, J.; Paddock, C.D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J.Y.; Cox, N.; Hughes, J.M.; LeDuc, J.W.; Bellini, W.J.; Anderson, L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med., 2003, 348(20), 1953-1966.
[http://dx.doi.org/10.1056/NEJMoa030781] [PMID: 12690092]

(a) Fouchier, R.A.M.; Kuiken, T.; Schutten, M.; van Amerongen, G.; van Doornum, G.J.J.; van den Hoogen, B.G.; Peiris, M.; Lim, W.; Stöhr, K.; Osterhaus, A.D.M.E. Koch’s postulates fulfilled for SARS virus. Nature, 2003, 423(6937), 240.;
(b) ) C., Rahul; H.K., Avathi; S.K., Sushanth; B.G., Reddy; D.P., Thammisetty; G.V., Nagaraju A Review on recent trends in corona virus disease prevention and treatment methods and research directions for future. Eur. Chem. Bull., 2023, 12(1), 786-807.
[http://dx.doi.org/10.1038/423240a] [PMID: 12748632]

Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.M.E.; Fouchier, R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med., 2012, 367(19), 1814-1820.
[http://dx.doi.org/10.1056/NEJMoa1211721] [PMID: 23075143]

Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]

Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H-R.; Zhu, Y.; Li, B.; Huang, C-L.; Chen, H-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R-D.; Liu, M-Q.; Chen, Y.; Shen, X-R.; Wang, X.; Zheng, X-S.; Zhao, K.; Chen, Q-J.; Deng, F.; Liu, L-L.; Yan, B.; Zhan, F-X.; Wang, Y-Y.; Xiao, G-F.; Shi, Z-L. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 588(7836), E6.
[http://dx.doi.org/10.1038/s41586-020-2951-z]

Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W.J.; Wang, D.; Xu, W.; Holmes, E.C.; Gao, G.F.; Wu, G.; Chen, W.; Shi, W.; Tan, W. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet, 2020, 395(10224), 565-574.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]

Chan, J.F.W.; Kok, K.H.; Zhu, Z.; Chu, H.; To, K.K.W.; Yuan, S.; Yuen, K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 2020, 9(1), 221-236.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]

Chen, L.; Liu, W.; Zhang, Q.; Xu, K.; Ye, G.; Wu, W.; Sun, Z.; Liu, F.; Wu, K.; Zhong, B.; Mei, Y.; Zhang, W.; Chen, Y.; Li, Y.; Shi, M.; Lan, K.; Liu, Y. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg. Microbes Infect., 2020, 9(1), 313-319.
[http://dx.doi.org/10.1080/22221751.2020.1725399] [PMID: 32020836]

Chan, J.F.W.; Yuan, S.; Kok, K.H.; To, K.K.W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C.C.Y.; Poon, R.W.S.; Tsoi, H.W.; Lo, S.K.F.; Chan, K.H.; Poon, V.K.M.; Chan, W.M.; Ip, J.D.; Cai, J.P.; Cheng, V.C.C.; Chen, H.; Hui, C.K.M.; Yuen, K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet, 2020, 395(10223), 514-523.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID: 31986261]

Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.S.M.; Lau, E.H.Y.; Wong, J.Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T.T.Y.; Wu, J.T.; Gao, G.F.; Cowling, B.J.; Yang, B.; Leung, G.M.; Feng, Z. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N. Engl. J. Med., 2020, 382(13), 1199-1207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]

Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]

Xu, X.; Chen, P.; Wang, J.; Feng, J.; Zhou, H.; Li, X.; Zhong, W.; Hao, P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci., 2020, 63(3), 457-460.
[http://dx.doi.org/10.1007/s11427-020-1637-5] [PMID: 32009228]

Guan, Y.; Zheng, B.J.; He, Y.Q.; Liu, X.L.; Zhuang, Z.X.; Cheung, C.L.; Luo, S.W.; Li, P.H.; Zhang, L.J.; Guan, Y.J.; Butt, K.M.; Wong, K.L.; Chan, K.W.; Lim, W.; Shortridge, K.F.; Yuen, K.Y.; Peiris, J.S.M.; Poon, L.L.M. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science, 2003, 302(5643), 276-278.
[http://dx.doi.org/10.1126/science.1087139] [PMID: 12958366]

Wang, M.; Yan, M.; Xu, H.; Liang, W.; Kan, B.; Zheng, B.; Chen, H.; Zheng, H.; Xu, Y.; Zhang, E.; Wang, H.; Ye, J.; Li, G.; Li, M.; Cui, Z.; Liu, Y.F.; Guo, R.T.; Liu, X.N.; Zhan, L.H.; Zhou, D.H.; Zhao, A.; Hai, R.; Yu, D.; Guan, Y.; Xu, J. SARS-CoV infection in a restaurant from palm civet. Emerg. Infect. Dis., 2005, 11(12), 1860-1865.
[http://dx.doi.org/10.3201/eid1112.041293] [PMID: 16485471]

Song, H.D.; Tu, C.C.; Zhang, G.W.; Wang, S.Y.; Zheng, K.; Lei, L.C.; Chen, Q.X.; Gao, Y.W.; Zhou, H.Q.; Xiang, H.; Zheng, H.J.; Chern, S.W.W.; Cheng, F.; Pan, C.M.; Xuan, H.; Chen, S.J.; Luo, H.M.; Zhou, D.H.; Liu, Y.F.; He, J.F.; Qin, P.Z.; Li, L.H.; Ren, Y.Q.; Liang, W.J.; Yu, Y.D.; Anderson, L.; Wang, M.; Xu, R.H.; Wu, X.W.; Zheng, H.Y.; Chen, J.D.; Liang, G.; Gao, Y.; Liao, M.; Fang, L.; Jiang, L.Y.; Li, H.; Chen, F.; Di, B.; He, L.J.; Lin, J.Y.; Tong, S.; Kong, X.; Du, L.; Hao, P.; Tang, H.; Bernini, A.; Yu, X.J.; Spiga, O.; Guo, Z.M.; Pan, H.Y.; He, W.Z.; Manuguerra, J.C.; Fontanet, A.; Danchin, A.; Niccolai, N.; Li, Y.X.; Wu, C.I.; Zhao, G.P. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl. Acad. Sci., 2005, 102(7), 2430-2435.
[http://dx.doi.org/10.1073/pnas.0409608102] [PMID: 15695582]

Shi, Z.; Hu, Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res., 2008, 133(1), 74-87.
[http://dx.doi.org/10.1016/j.virusres.2007.03.012] [PMID: 17451830]

Li, W.; Shi, Z.; Yu, M.; Ren, W.; Smith, C.; Epstein, J.H.; Wang, H.; Crameri, G.; Hu, Z.; Zhang, H.; Zhang, J.; McEachern, J.; Field, H.; Daszak, P.; Eaton, B.T.; Zhang, S.; Wang, L.F. Bats are natural reservoirs of SARS-like coronaviruses. Science, 2005, 310(5748), 676-679.
[http://dx.doi.org/10.1126/science.1118391] [PMID: 16195424]

Lau, S.K.P.; Woo, P.C.Y.; Li, K.S.M.; Huang, Y.; Tsoi, H.W.; Wong, B.H.L.; Wong, S.S.Y.; Leung, S.Y.; Chan, K.H.; Yuen, K.Y. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci., 2005, 102(39), 14040-14045.
[http://dx.doi.org/10.1073/pnas.0506735102] [PMID: 16169905]

Ge, X.Y.; Li, J.L.; Yang, X.L.; Chmura, A.A.; Zhu, G.; Epstein, J.H.; Mazet, J.K.; Hu, B.; Zhang, W.; Peng, C.; Zhang, Y.J.; Luo, C.M.; Tan, B.; Wang, N.; Zhu, Y.; Crameri, G.; Zhang, S.Y.; Wang, L.F.; Daszak, P.; Shi, Z.L. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature, 2013, 503(7477), 535-538.
[http://dx.doi.org/10.1038/nature12711] [PMID: 24172901]

Hu, B.; Zeng, L.P.; Yang, X.L.; Ge, X.Y.; Zhang, W.; Li, B.; Xie, J.Z.; Shen, X.R.; Zhang, Y.Z.; Wang, N.; Luo, D.S.; Zheng, X.S.; Wang, M.N.; Daszak, P.; Wang, L.F.; Cui, J.; Shi, Z.L. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog., 2017, 13(11), e1006698.
[http://dx.doi.org/10.1371/journal.ppat.1006698] [PMID: 29190287]

Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; Yuan, M.L.; Zhang, Y.L.; Dai, F.H.; Liu, Y.; Wang, Q.M.; Zheng, J.J.; Xu, L.; Holmes, E.C.; Zhang, Y.Z. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798), 265-269.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]

Jiang, S.; Du, L.; Shi, Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: Calling for developing therapeutic and prophylactic strategies. Emerg. Microbes Infect., 2020, 9(1), 275-277.
[http://dx.doi.org/10.1080/22221751.2020.1723441] [PMID: 32005086]

Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J. Virol., 2020, 94(7), e00127-20.
[http://dx.doi.org/10.1128/JVI.00127-20] [PMID: 31996437]

Giovanetti, M.; Benedetti, F.; Campisi, G.; Ciccozzi, A.; Fabris, S.; Ceccarelli, G.; Tambone, V.; Caruso, A.; Angeletti, S.; Zella, D.; Ciccozzi, M. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem. Biophys. Res. Commun., 2021, 538, 88-91.
[http://dx.doi.org/10.1016/j.bbrc.2020.10.102] [PMID: 33199021]

Galloway, S.E.; Paul, P.; MacCannell, D.R.; Johansson, M.A.; Brooks, J.T.; MacNeil, A.; Slayton, R.B.; Tong, S.; Silk, B.J.; Armstrong, G.L.; Biggerstaff, M.; Dugan, V.G. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb. Mortal. Wkly. Rep., 2021, 70(3), 95-99.
[http://dx.doi.org/10.15585/mmwr.mm7003e2] [PMID: 33476315]

(a) Davies, N.G.; Abbott, S.; Barnard, R.C.; Jarvis, C.I.; Kucharski, A.J.; Munday, J.D.; Pearson, C.A.B.; Russell, T.W.; Tully, D.C.; Washburne, A.D.; Wenseleers, T.; Gimma, A.; Waites, W.; Wong, K.L.M.; van Zandvoort, K.; Silverman, J.D.; Diaz-Ordaz, K.; Keogh, R.; Eggo, R.M.; Funk, S.; Jit, M.; Atkins, K.E.; Edmunds, W.J. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science, 2021, 372(6538), eabg3055.
[http://dx.doi.org/10.1126/science.abg3055] [PMID: 33658326];
(b) Hoteit, R.; Yassine, H.M Biological properties of SARS-CoV- -2 variants: Epidemiological impact and clinical consequences Vaccines, 2022, 10(6), 919.
[http://dx.doi.org/10.3390/vaccines10060919]

Walensky, R.P.; Walke, H.T.; Fauci, A.S. SARS-CoV-2 variants of concern in the united states-challenges and opportunities. JAMA, 2021, 325(11), 1037-1038.
[http://dx.doi.org/10.1001/jama.2021.2294] [PMID: 33595644]

Wu, K.; Werner, A.P.; Moliva, J.I.; Koch, M.; Choi, A.; Stewart-Jones, G.B.E.; Bennett, H.; Boyoglu-Barnum, S.; Shi, W.; Graham, B.S.; Carfi, A.; Corbett, K.S.; Seder, R.A.; Edwards, D.K.; Wu, K; Werner, AP; Moliva, JI; Koch, M; Choi, A; Stewart-Jones, GBE; Bennett, H; Boyoglu-Barnum, S; Shi, W; Graham, BS; Carfi, A; Corbett, KS; Seder, RA; Edwards, DK mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv, 2021.
[http://dx.doi.org/10.1101/2021.01.25.427948]

Volz, E.; Mishra, S.; Chand, M.; Barrett, J.C.; Johnson, R.; Geidelberg, L.; Hinsley, W.R.; Laydon, D.J.; Dabrera, G.; O’Toole, Á.; Amato, R.; Ragonnet-Cronin, M.; Harrison, I.; Jackson, B.; Ariani, C.V.; Boyd, O.; Loman, N.J.; McCrone, J.T.; Gonçalves, S.; Jorgensen, D.; Myers, R.; Hill, V.; Jackson, D.K.; Gaythorpe, K.; Groves, N.; Sillitoe, J.; Kwiatkowski, D.P.; Flaxman, S.; Ratmann, O.; Bhatt, S.; Hopkins, S.; Gandy, A.; Rambaut, A.; Ferguson, N.M. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature, 2021, 593(7858), 266-269.
[http://dx.doi.org/10.1038/s41586-021-03470-x] [PMID: 33767447]

Tegally, H.; Wilkinson, E.; Giovanetti, M.; Iranzadeh, A.; Fonseca, V.; Giandhari, J.; Doolabh, D.; Pillay, S.; San, E.J.; Msomi, N.; Mlisana, K.; von Gottberg, A.; Walaza, S.; Allam, M.; Ismail, A.; Mohale, T.; Glass, A.J.; Engelbrecht, S.; Van Zyl, G.; Preiser, W.; Petruccione, F.; Sigal, A.; Hardie, D.; Marais, G.; Hsiao, N.; Korsman, S.; Davies, M.A.; Tyers, L.; Mudau, I.; York, D.; Maslo, C.; Goedhals, D.; Abrahams, S.; Laguda-Akingba, O.; Alisoltani-Dehkordi, A.; Godzik, A.; Wibmer, C.K.; Sewell, B.T.; Lourenço, J.; Alcantara, L.C.J.; Kosakovsky Pond, S.L.; Weaver, S.; Martin, D.; Lessells, R.J.; Bhiman, J.N.; Williamson, C.; de Oliveira, T. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592(7854), 438-443.
[http://dx.doi.org/10.1038/s41586-021-03402-9] [PMID: 33690265]

Wibmer, C.K.; Ayres, F.; Hermanus, T.; Madzivhandila, M.; Kgagudi, P.; Oosthuysen, B.; Lambson, B.E.; de Oliveira, T.; Vermeulen, M.; Van der Berg, K.; Rossouw, T.; Boswell, M.; Ueckermann, V.; Meiring, S.; Von Gottberg, A.; Cohen, C.; Morris, L.; Bhiman, J.N.; Moore, P.L. SARS-CoV-2 501Y. bioRxiv, 2021.

Mwenda, M.; Saasa, N.; Sinyange, N.; Busby, G.; Chipimo, P.J.; Hendry, J.; Kapona, O.; Yingst, S.; Hines, J.Z.; Minchella, P.; Simulundu, E.; Changula, K.; Nalubamba, K.S.; Sawa, H.; Kajihara, M.; Yamagishi, J.; Kapin’a, M.; Kapata, N.; Fwoloshi, S.; Zulu, P.; Mulenga, L.B.; Agolory, S.; Mukonka, V.; Bridges, D.J. Detection of B.1.351 SARS-CoV-2 variant strain-zambia, december 2020. MMWR Morb. Mortal. Wkly. Rep., 2021, 70(8), 280-282.
[http://dx.doi.org/10.15585/mmwr.mm7008e2] [PMID: 33630820]

Wang, P.; Casner, R.G.; Nair, M.S.; Wang, M.; Yu, J.; Cerutti, G.; Liu, L.; Kwong, P.D.; Huang, Y.; Shapiro, L.; Ho, D.D. Increased resistance of SARS-CoV-2 variant. bioRxiv, 2021.

Vaughan, A.; Mellan, T.A.; Whittaker, C.; Claro, I.M.; Candido, D.D.S.; Mishra, S.; Crispim, M.A.E.; Sales, F.C.; Hawryluk, I.; McCrone, J.T.; Hulswit, R.J.G.; Franco, L.A.M.; Ramundo, M.S.; de Jesus, J.G.; Andrade, P.S.; Coletti, T.M.; Ferreira, G.M.; Silva, C.A.M.; Manuli, E.R.; Pereira, R.H.M.; Peixoto, P.S.; Kraemer, M.U.; Gaburo, N.; Camilo, C.D.C.; Hoeltgebaum, H.; Souza, W.M.; Rocha, E.C.; de Souza, L.M.; de Pinho, M.C.; Araujo, L.J.T.; Malta, F.S.V.; de Lima, A.B.; Silva, J.D.P.; Zauli, D.A.G. Omicron emerges. New Sci., 2021, 252(3363), 7.
[http://dx.doi.org/10.1016/S0262-4079(21)02140-0] [PMID: 34876769]

Callaway, E. Heavily mutated Omicron variant puts scientists on alert. Nature, 2021, 600(7887), 21.
[http://dx.doi.org/10.1038/d41586-021-03552-w] [PMID: 34824381]

Gu, H.; Krishnan, P.; Ng, D.Y.M.; Chang, L.D.J.; Liu, G.Y.Z.; Cheng, S.S.M.; Hui, M.M.Y.; Fan, M.C.Y.; Wan, J.H.L.; Lau, L.H.K.; Cowling, B.J.; Peiris, M.; Poon, L.L.M. Probable transmission of SARS-CoV-2 omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg. Infect. Dis., 2022, 28(2), 460-462.
[http://dx.doi.org/10.3201/eid2802.212422] [PMID: 34860154]

Chen, J; Wang, R; Gilby, NB; Wei, GW Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv., 2021.

Yue, C.; Song, W.; Wang, L.; Jian, F.; Chen, X.; Gao, F.; Shen, Z.; Wang, Y.; Wang, X.; Cao, Y. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect. Dis., 2023, 23(3), 278-280.
[http://dx.doi.org/10.1016/S1473-3099(23)00010-5] [PMID: 36746173]

Zhang, W.; Davis, B.D.; Chen, S.S.; Sincuir Martinez, J.M.; Plummer, J.T.; Vail, E. Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA, 2021, 325(13), 1324-1326.
[http://dx.doi.org/10.1001/jama.2021.1612] [PMID: 33571356]

Voloch, C.M.; da Silva Francisco, R., Jr; de Almeida, L.G.P.; Cardoso, C.C.; Brustolini, O.J.; Gerber, A.L.; Guimarães, A.P.C.; Mariani, D.; da Costa, R.M.; Ferreira, O.C., Jr; Cavalcanti, A.C.; Frauches, T.S.; de Mello, C.M.B.; Leitão, I.C.; Galliez, R.M.; Faffe, D.S.; Castiñeiras, T.M.P.P.; Tanuri, A.; de Vasconcelos, A.T.R. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J. Virol., 2021, 95(10), e00119-21.
[http://dx.doi.org/10.1128/JVI.00119-21] [PMID: 33649194]

Tracking SARS-CoV-2 variants. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (Accessed on: January 3, 2022).

Gorbalenya, A.E.; Baker, S.C.; Baric, R.S.; de Groot, R.J.; Drosten, C.; Gulyaeva, A.A.; Haagmans, B.L.; Lauber, C.; Leontovich, A.M.; Neuman, B.W.; Penzar, D.; Perlman, S.; Poon, L.L.M.; Samborskiy, D.V.; Sidorov, I.A.; Sola, I.; Ziebuhr, J. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 2020, 5(4), 536-544.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]

Davies, N.G.; Jarvis, C.I.; Edmunds, WJ; Jewell, NP; Diaz-Ordaz, K; Keogh, RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature, 2021, 593(7858), 270-4.
[http://dx.doi.org/10.1101/2021.02.01.21250959]

Rodrigues, E.F.; Moreno, J.; Leite, P.P.; Casaca, P.; Nunes, B.; Gomes, J.P.; Ferreira, R.; Isidro, J.; Borges, V.; Vieira, L.; Duarte, S.; Sousa, C.; Almeida, J.P.; Menezes, L.; Vaz, D.; Leite, A.; Peralta-Santos, A. B.1.617.2 SARS-CoV-2 (Delta) variant is associated with increased risk of hospitalization and death compared with B.1.1.7 SARS-CoV-2 (Alpha) variant. medRix, 2022, 2, 20122.
[http://dx.doi.org/10.1101/2022.01.21.22268602]

Radvak, P.; Kwon, H.J.; Kosikova, M.; Ortega-Rodriguez, U.; Xiang, R.; Phue, J.N.; Shen, R.F.; Rozzelle, J.; Kapoor, N.; Rabara, T.; Fairman, J.; Xie, H. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat. Commun., 2021, 12(1), 6559.
[http://dx.doi.org/10.1038/s41467-021-26803-w] [PMID: 34772941]

Liu, H.; Wei, P.; Zhang, Q.; Chen, Z.; Aviszus, K.; Downing, W.; Peterson, S.; Reynoso, L.; Downey, G.P.; Frankel, S.K.; Kappler, J.; Marrack, P.; Zhang, G. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro. MAbs, 2021, 13(1), 1919285.
[http://dx.doi.org/10.1080/19420862.2021.1919285] [PMID: 34074219]

Coutinho, R.M.; Marquitti, F.M.D.; Ferreira, L.S.; Borges, M.E.; da Silva, R.L.P.; Canton, O.; Portella, T.P.; Poloni, S.; Franco, C.; Plucinski, M.M.; Lessa, F.C.; da Silva, A.A.M.; Kraenkel, R.A.; de Sousa, M.V.M.A.; Prado, P.I. Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. Commun. Med., 2021, 1(1), 48.
[http://dx.doi.org/10.1038/s43856-021-00048-6] [PMID: 35602219]

Dong, E.; Du, H.; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis., 2020, 20(5), 533-534.
[http://dx.doi.org/10.1016/S1473-3099(20)30120-1] [PMID: 32087114]

Spira, B. The impact of the highly virulent SARS-CoV-2 gamma variant on young adults in the State of São Paulo: Was it inevitable? Cureus, 2022, 14(7), e26486.
[http://dx.doi.org/10.7759/cureus.26486] [PMID: 35919213]

Dawood, F.S.; Porucznik, C.A.; Veguilla, V.; Stanford, J.B.; Duque, J.; Rolfes, M.A.; Dixon, A.; Thind, P.; Hacker, E.; Castro, M.J.E.; Jeddy, Z.; Daugherty, M.; Altunkaynak, K.; Hunt, D.R.; Kattel, U.; Meece, J.; Stockwell, M.S. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in utah and New York City, New York. JAMA Pediatr., 2022, 176(1), 59-67.
[http://dx.doi.org/10.1001/jamapediatrics.2021.4217] [PMID: 34623377]

Dhawan, M.; Sharma, A.; Priyanka; Thakur, N.; Rajkhowa, T.K.; Choudhary, O.P. Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Hum. Vaccin. Immunother., 2022, 18(5), 2068883.
[http://dx.doi.org/10.1080/21645515.2022.2068883] [PMID: 35507895]

Chakraborty, C.; Bhattacharya, M.; Sharma, A.R.; Mallik, B. Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int. J. Biol. Macromol., 2022, 219, 980-997.
[http://dx.doi.org/10.1016/j.ijbiomac.2022.07.254] [PMID: 35952818]

Ward, I.L.; Bermingham, C.; Ayoubkhani, D.; Gethings, O.J.; Pouwels, K.B.; Yates, T.; Khunti, K.; Hippisley-Cox, J.; Banerjee, A.; Walker, A.S.; Nafilyan, V. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): Retrospective cohort study. BMJ, 2022, 378, e070695.
[http://dx.doi.org/10.1136/bmj-2022-070695] [PMID: 35918098]

Allen, H.; Tessier, E.; Turner, C.; Anderson, C.; Blomquist, P.; Simons, D.; Løchen, A.; Jarvis, C.I.; Groves, N.; Capelastegui, F.; Flannagan, J.; Zaidi, A.; Chen, C.; Rawlinson, C.; Hughes, G.J.; Chudasama, D.; Nash, S.; Thelwall, S.; Lopez-Bernal, J.; Dabrera, G.; Charlett, A.; Kall, M.; Lamagni, T. Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: National cohort study, England. Epidemiol. Infect., 2023, 151, e58.
[http://dx.doi.org/10.1017/S0950268823000420] [PMID: 36938806]

Wang, P.; Nair, M.S.; Liu, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P.D.; Graham, B.S.; Mascola, J.R.; Chang, J.Y.; Yin, M.T.; Sobieszczyk, M.; Kyratsous, C.A.; Shapiro, L.; Sheng, Z.; Huang, Y.; Ho, D.D. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv, 2021, 2021.01.25.428137.
[http://dx.doi.org/10.21203/rs.3.rs-155394/v1]

Köhler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J. Immunol., 2005, 174(5), 2453-2455.
[PMID: 15728446]

Hansel, T.T.; Kropshofer, H.; Singer, T.; Mitchell, J.A.; George, A.J.T. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov., 2010, 9(4), 325-338.
[http://dx.doi.org/10.1038/nrd3003] [PMID: 20305665]

Both, L.; Banyard, A.C.; van Dolleweerd, C.; Wright, E.; Ma, J.K.C.; Fooks, A.R. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Pediatr. Pol., 2013, 88(5), T15-T23.
[http://dx.doi.org/10.1016/j.pepo.2013.08.006] [PMID: 32287402]

Asherson, R.A.; Gunter, K.; Daya, D.; Shoenfeld, Y. Multiple autoimmune diseases in a young woman: Tuberculosis and splenectomy as possible triggering factors? Another example of the “mosaic” of autoimmunity. J. Rheumatol., 2008, 35(6), 1224-1226.
[PMID: 18528954]

Waudby-West, R.; Parcell, B.J.; Palmer, C.N.A.; Bell, S.; Chalmers, J.D.; Siddiqui, M.K. The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort. Eur. Respir. J., 2021, 58(1), 2100360.
[http://dx.doi.org/10.1183/13993003.00360-2021] [PMID: 34172468]

Abdulrahman, A.; Mallah, S.I.; Alawadhi, A.; Perna, S.; Janahi, E.M.; AlQahtani, M.M. Association between RT-PCR Ct values and COVID-19 new daily cases: A multicenter cross-sectional study. medRxiv, 2020, 29(3), 416.
[http://dx.doi.org/10.1101/2020.12.07.20245233]

Karahasan Yagci, A.; Sarinoglu, R.C.; Bilgin, H.; Yanılmaz, Ö.; Sayın, E.; Deniz, G.; Guncu, M.M.; Doyuk, Z.; Barıs, C.; Kuzan, B.N.; Aslan, B.; Korten, V.; Cimsit, C. Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain reaction and total severity score of computerized tomography in patients with COVID 19. Int. J. Infect. Dis., 2020, 101, 160-166.
[http://dx.doi.org/10.1016/j.ijid.2020.09.1449] [PMID: 32992013]

Anaclerio, F.; Ferrante, R.; Mandatori, D.; Antonucci, I.; Capanna, M.; Damiani, V.; Tomo, P.D.; Ferrante, R.; Ranaudo, M.; De Laurenzi, V.; Stuppia, L.; De Fabritiis, S. Different strategies for the identification of SARS-CoV-2 variants in the laboratory practice. Genes, 2021, 12(9), 1428.
[http://dx.doi.org/10.3390/genes12091428] [PMID: 34573410]

Vega-Magaña, N.; Sánchez-Sánchez, R.; Hernández-Bello, J.; Venancio-Landeros, A.A.; Peña-Rodríguez, M.; Vega-Zepeda, R.A.; Galindo-Ornelas, B.; Díaz-Sánchez, M.; García-Chagollán, M.; Macedo-Ojeda, G.; García-González, O.P.; Muñoz-Valle, J.F. RT-qPCR assays for rapid detection of the N501Y, 69-70del, K417N, and E484K SARS-CoV-2 mutations: A screening strategy to identify variants with clinical impact. Front. Cell. Infect. Microbiol., 2021, 11, 672562.
[http://dx.doi.org/10.3389/fcimb.2021.672562] [PMID: 34123874]

Aguilar-Shea, A.L.; Vera-García, M.; Güerri-Fernández, R. Rapid antigen tests for the detection of SARS-CoV-2: A narrative review. Aten. Primaria, 2021, 53(9), 102127.
[http://dx.doi.org/10.1016/j.aprim.2021.102127] [PMID: 34217106]

Verma, M.K.; Sharma, P.K.; Verma, H.K.; Singh, A.N.; Singh, D.D.; Verma, P.; Siddiqui, A.H. Rapid diagnostic methods for SARS-CoV-2 (COVID-19) detection: An evidence-based report. J. Med. Life, 2021, 14(4), 431-442.
[http://dx.doi.org/10.25122/jml-2021-0168] [PMID: 34621365]

Mandal, D.K.; Bhattarai, B.R.; Pokhrel, S.; Chhusyabaga, M.; Bhandari, P.; Bhatt, M.P.; Marhattha, S.B. Diagnostic performance of SARS-CoV-2 rapid antigen test in relation to RT-PCR C_q Value. Adv. Virol., 2022, 2022, 1-8.
[http://dx.doi.org/10.1155/2022/9245248] [PMID: 35592595]

Wise, J. Covid-19: New coronavirus variant is identified in UK. BMJ, 2020, 371, m4857.
[http://dx.doi.org/10.1136/bmj.m4857] [PMID: 33328153]

Gottlieb, R.L.; Nirula, A.; Chen, P.; Boscia, J.; Heller, B.; Morris, J.; Huhn, G.; Cardona, J.; Mocherla, B.; Stosor, V.; Shawa, I.; Kumar, P.; Adams, A.C.; Van Naarden, J.; Custer, K.L.; Durante, M.; Oakley, G.; Schade, A.E.; Holzer, T.R.; Ebert, P.J.; Higgs, R.E.; Kallewaard, N.L.; Sabo, J.; Patel, D.R.; Klekotka, P.; Shen, L.; Skovronsky, D.M. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA, 2021, 325(7), 632-644.
[http://dx.doi.org/10.1001/jama.2021.0202] [PMID: 33475701]

Westendorf, K.; Žentelis, S.; Wang, L.; Foster, D.; Vaillancourt, P.; Wiggin, M.; Lovett, E.; van der Lee, R.; Hendle, J.; Pustilnik, A.; Sauder, J.M.; Kraft, L.; Hwang, Y.; Siegel, R.W.; Chen, J.; Heinz, B.A.; Higgs, R.E.; Kallewaard, N.L.; Jepson, K.; Goya, R.; Smith, M.A.; Collins, D.W.; Pellacani, D.; Xiang, P.; de Puyraimond, V.; Ricicova, M.; Devorkin, L.; Pritchard, C.; O’Neill, A.; Dalal, K.; Panwar, P.; Dhupar, H.; Garces, F.A.; Cohen, C.A.; Dye, J.M.; Huie, K.E.; Badger, C.V.; Kobasa, D.; Audet, J.; Freitas, J.J.; Hassanali, S.; Hughes, I.; Munoz, L.; Palma, H.C.; Ramamurthy, B.; Cross, R.W.; Geisbert, T.W.; Menacherry, V.; Lokugamage, K.; Borisevich, V.; Lanz, I.; Anderson, L.; Sipahimalani, P.; Corbett, K.S.; Yang, E.S.; Zhang, Y.; Shi, W.; Zhou, T.; Choe, M.; Misasi, J.; Kwong, P.D.; Sullivan, N.J.; Graham, B.S.; Fernandez, T.L.; Hansen, C.L.; Falconer, E.; Mascola, J.R.; Jones, B.E.; Barnhart, B.C. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv, 2022.

Levin, M.J.; Ustianowski, A.; De Wit, S.; Launay, O.; Avila, M.; Templeton, A.; Yuan, Y.; Seegobin, S.; Ellery, A.; Levinson, D.J.; Ambery, P.; Arends, R.H.; Beavon, R.; Dey, K.; Garbes, P.; Kelly, E.J.; Koh, G.C.K.W.; Near, K.A.; Padilla, K.W.; Psachoulia, K.; Sharbaugh, A.; Streicher, K.; Pangalos, M.N.; Esser, M.T. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19. N. Engl. J. Med., 2022, 386(23), 2188-2200.
[http://dx.doi.org/10.1056/NEJMoa2116620] [PMID: 35443106]

Dong, J.; Zost, S.J.; Greaney, A.J.; Starr, T.N.; Dingens, A.S.; Chen, E.C.; Chen, R.E.; Case, J.B.; Sutton, R.E.; Gilchuk, P.; Rodriguez, J.; Armstrong, E.; Gainza, C.; Nargi, R.S.; Binshtein, E.; Xie, X.; Zhang, X.; Shi, P.Y.; Logue, J.; Weston, S.; McGrath, M.E.; Frieman, M.B.; Brady, T.; Tuffy, K.M.; Bright, H.; Loo, Y.M.; McTamney, P.M.; Esser, M.T.; Carnahan, R.H.; Diamond, M.S.; Bloom, J.D.; Crowe, J.E., Jr Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol., 2021, 6(10), 1233-1244.
[http://dx.doi.org/10.1038/s41564-021-00972-2] [PMID: 34548634]

Zost, S.J.; Gilchuk, P.; Case, J.B.; Binshtein, E.; Chen, R.E.; Nkolola, J.P.; Schäfer, A.; Reidy, J.X.; Trivette, A.; Nargi, R.S.; Sutton, R.E.; Suryadevara, N.; Martinez, D.R.; Williamson, L.E.; Chen, E.C.; Jones, T.; Day, S.; Myers, L.; Hassan, A.O.; Kafai, N.M.; Winkler, E.S.; Fox, J.M.; Shrihari, S.; Mueller, B.K.; Meiler, J.; Chandrashekar, A.; Mercado, N.B.; Steinhardt, J.J.; Ren, K.; Loo, Y.M.; Kallewaard, N.L.; McCune, B.T.; Keeler, S.P.; Holtzman, M.J.; Barouch, D.H.; Gralinski, L.E.; Baric, R.S.; Thackray, L.B.; Diamond, M.S.; Carnahan, R.H.; Crowe, J.E., Jr Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 2020, 584(7821), 443-449.
[http://dx.doi.org/10.1038/s41586-020-2548-6] [PMID: 32668443]

Beavis, K.G.; Matushek, S.M.; Abeleda, A.P.F.; Bethel, C.; Hunt, C.; Gillen, S.; Moran, A.; Tesic, V. Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies. J. Clin. Virol., 2020, 129, 104468.
[http://dx.doi.org/10.1016/j.jcv.2020.104468] [PMID: 32485620]

Ghaffari, A.; Meurant, R.; Ardakani, A. COVID-19 serological tests: How well do they actually perform. Diagnostics, 2020, 10(7), 453.
[http://dx.doi.org/10.3390/diagnostics10070453] [PMID: 32635444]

Lisboa Bastos, M.; Tavaziva, G.; Abidi, S.K.; Campbell, J.R.; Haraoui, L.P.; Johnston, J.C.; Lan, Z.; Law, S.; MacLean, E.; Trajman, A.; Menzies, D.; Benedetti, A.; Ahmad Khan, F. Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis. BMJ, 2020, 370, m2516.
[http://dx.doi.org/10.1136/bmj.m2516] [PMID: 32611558]

Ni, Y.N.; Luo, J.; Yu, H.; Liu, D.; Liang, B.M.; Liang, Z.A. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am. J. Emerg. Med., 2018, 36(2), 226-233.
[http://dx.doi.org/10.1016/j.ajem.2017.07.083] [PMID: 28780231]

Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2), 271-280.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]

Avorn, J. Learning about the safety of drugs--a half-century of evolution. N. Engl. J. Med., 2011, 365(23), 2151-2153.
[http://dx.doi.org/10.1056/NEJMp1110327] [PMID: 22150034]

Yuen, C.K.; Lam, J.Y.; Wong, W.M.; Mak, L.F.; Wang, X.; Chu, H.; Cai, J.P.; Jin, D.Y.; To, K.K.W.; Chan, J.F.W.; Yuen, K.Y.; Kok, K.H. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg. Microbes Infect., 2020, 9(1), 1418-1428.
[http://dx.doi.org/10.1080/22221751.2020.1780953] [PMID: 32529952]

Ranieri, V.M.; Pettilä, V.; Karvonen, M.K.; Jalkanen, J.; Nightingale, P.; Brealey, D.; Mancebo, J.; Ferrer, R.; Mercat, A.; Patroniti, N.; Quintel, M.; Vincent, J.L.; Okkonen, M.; Meziani, F.; Bellani, G.; MacCallum, N.; Creteur, J.; Kluge, S.; Artigas-Raventos, A.; Maksimow, M.; Piippo, I.; Elima, K.; Jalkanen, S.; Jalkanen, M.; Bellingan, G. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome. JAMA, 2020, 323(8), 725-733.
[http://dx.doi.org/10.1001/jama.2019.22525] [PMID: 32065831]

Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M.S. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob. Agents Chemother., 2020, 64(9), e01061-20.
[http://dx.doi.org/10.1128/AAC.01061-20] [PMID: 32661006]

Sosa, J.P.; Ferreira Caceres, M.M.; Ross Comptis, J.; Quiros, J.; Príncipe-Meneses, F.S.; Riva-Moscoso, A.; Belizaire, M.P.; Malanyaon, F.Q.; Agadi, K.; Jaffery, S.S.; Sahajwani, J.; Arshia, A.; Senatus, A.; Verdecia, G.; Akano, L.; Razzack, A.A.; Salam, S.; Gadamidi, V.K.; Marian, S. Effects of interferon beta in COVID-19 adult patients: Systematic review. Infect. Chemother., 2021, 53(2), 247-260.
[http://dx.doi.org/10.3947/ic.2021.0028] [PMID: 34216119]

Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J.K.; Haynes, R.; Landray, M.J. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med., 2021, 384(8), 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]

Huet, T.; Beaussier, H.; Voisin, O.; Jouveshomme, S.; Dauriat, G.; Lazareth, I.; Sacco, E.; Naccache, J.M.; Bézie, Y.; Laplanche, S.; Le Berre, A.; Le Pavec, J.; Salmeron, S.; Emmerich, J.; Mourad, J.J.; Chatellier, G.; Hayem, G. Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol., 2020, 2(7), e393-e400.
[http://dx.doi.org/10.1016/S2665-9913(20)30164-8] [PMID: 32835245]

Conti, P.; Ronconi, G.; Caraffa, A.; Gallenga, C.E.; Ross, R.; Frydas, I.; Kritas, S.K. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents, 2020, 34(2), 327-331.
[PMID: 32171193]

Cellina, M.; Orsi, M.; Bombaci, F.; Sala, M.; Marino, P.; Oliva, G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn. Interv. Imaging, 2020, 101(5), 323-324.
[http://dx.doi.org/10.1016/j.diii.2020.03.010] [PMID: 32278585]

Michot, J.M.; Albiges, L.; Chaput, N.; Saada, V.; Pommeret, F.; Griscelli, F.; Balleyguier, C.; Besse, B.; Marabelle, A.; Netzer, F.; Merad, M.; Robert, C.; Barlesi, F.; Gachot, B.; Stoclin, A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: A case report. Ann. Oncol., 2020, 31(7), 961-964.
[http://dx.doi.org/10.1016/j.annonc.2020.03.300] [PMID: 32247642]

Rosas, I.O.; Bräu, N.; Waters, M.; Go, R.C.; Hunter, B.D.; Bhagani, S.; Skiest, D.; Aziz, M.S.; Cooper, N.; Douglas, I.S.; Savic, S.; Youngstein, T.; Del Sorbo, L.; Cubillo Gracian, A.; De La Zerda, D.J.; Ustianowski, A.; Bao, M.; Dimonaco, S.; Graham, E.; Matharu, B.; Spotswood, H.; Tsai, L.; Malhotra, A. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N. Engl. J. Med., 2021, 384(16), 1503-1516.
[http://dx.doi.org/10.1056/NEJMoa2028700] [PMID: 33631066]

Stone, J.H.; Frigault, M.J.; Serling-Boyd, N.J.; Fernandes, A.D.; Harvey, L.; Foulkes, A.S.; Horick, N.K.; Healy, B.C.; Shah, R.; Bensaci, A.M.; Woolley, A.E.; Nikiforow, S.; Lin, N.; Sagar, M.; Schrager, H.; Huckins, D.S.; Axelrod, M.; Pincus, M.D.; Fleisher, J.; Sacks, C.A.; Dougan, M.; North, C.M.; Halvorsen, Y.D.; Thurber, T.K.; Dagher, Z.; Scherer, A.; Wallwork, R.S.; Kim, A.Y.; Schoenfeld, S.; Sen, P.; Neilan, T.G.; Perugino, C.A.; Unizony, S.H.; Collier, D.S.; Matza, M.A.; Yinh, J.M.; Bowman, K.A.; Meyerowitz, E.; Zafar, A.; Drobni, Z.D.; Bolster, M.B.; Kohler, M.; D’Silva, K.M.; Dau, J.; Lockwood, M.M.; Cubbison, C.; Weber, B.N.; Mansour, M.K. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med., 2020, 383(24), 2333-2344.
[http://dx.doi.org/10.1056/NEJMoa2028836] [PMID: 33085857]

Gordon, A.C.; Mouncey, P.R.; Al-Beidh, F.; Rowan, K.M.; Nichol, A.D.; Arabi, Y.M.; Annane, D.; Beane, A.; van Bentum-Puijk, W.; Berry, L.R.; Bhimani, Z.; Bonten, M.J.M.; Bradbury, C.A.; Brunkhorst, F.M.; Buzgau, A.; Cheng, A.C.; Detry, M.A.; Duffy, E.J.; Estcourt, L.J.; Fitzgerald, M.; Goossens, H.; Haniffa, R.; Higgins, A.M.; Hills, T.E.; Horvat, C.M.; Lamontagne, F.; Lawler, P.R.; Leavis, H.L.; Linstrum, K.M.; Litton, E.; Lorenzi, E.; Marshall, J.C.; Mayr, F.B.; McAuley, D.F.; McGlothlin, A.; McGuinness, S.P.; McVerry, B.J.; Montgomery, S.K.; Morpeth, S.C.; Murthy, S.; Orr, K.; Parke, R.L.; Parker, J.C.; Patanwala, A.E.; Pettilä, V.; Rademaker, E.; Santos, M.S.; Saunders, C.T.; Seymour, C.W.; Shankar-Hari, M.; Sligl, W.I.; Turgeon, A.F.; Turner, A.M.; van de Veerdonk, F.L.; Zarychanski, R.; Green, C.; Lewis, R.J.; Angus, D.C.; McArthur, C.J.; Berry, S.; Webb, S.A.; Derde, L.P.G. Interleukin-6 receptor antagonists in critically Ill patients with covid-19. N. Engl. J. Med., 2021, 384(16), 1491-1502.
[http://dx.doi.org/10.1056/NEJMoa2100433] [PMID: 33631065]

Lescure, F.X.; Honda, H.; Fowler, R.A.; Lazar, J.S.; Shi, G.; Wung, P.; Patel, N.; Hagino, O.; Bazzalo, I.J.; Casas, M.M.; Nuñez, S.A.; Pere, Y.; Ibarrola, C.M.; Solis, A.M.A.; Cuesta, M.C.; Duarte, A.E.; Gutierrez, F.P.M.; Iannantuono, M.A.; Miyazaki, E.A.; Silvio, J.P.; Scublinsky, D.G.; Bales, A.; Catarino, D.; Fiss, E.; Mohrbacher, S.; Sato, V.; Baylao, A.; Cavalcante, A.; Correa, F.; de Andrade, C.A.; Furtado, J.; Ribeiro, F.N.; Telles, V.; Trevelin, L.T.; Vipich, R.; Boldo, R.; Borges, P.; Lobo, S.; Luckemeyer, G.; Machado, L.; Alves, M.B.; Iglessias, A.C.; Lago, M.M.; Santos, D.W.; Chapdelaine, H.; Falcone, E.L.; Jamal, R.; Luong, M-L.; Durand, M.; Doucet, S.; Carrier, F-M.; Coburn, B.A.; Del Sorbo, L.; Walmsley, S.L.; Belga, S.; Chen, L.Y.; Mah, A.D.; Steiner, T.; Wright, A.J.; Hajek, J.; Adhikari, N.; Fowler, R.A.; Daneman, N.; Khwaja, K.A.; Shahin, J.; Gonzalez, C.; Silva, R.; Lindh, M.; Maluenda, G.; Fernandez, P.; Oyonarte, M.; Lasso, M.; Boyer, A.; Bronnimann, D.; Bui, H-N.; Cazanave, C.; Chaussade, H.; Desclaux, A.; Ducours, M.; Duvignaud, A.; Malvy, D.; Martin, L.; Neau, D.; Nguyen, D.; Pistone, T.; Soubrane-Wirth, G.; Leitao, J.; Allavena, C.; Biron, C.; Bouchez, S.; Gaborit, B.; Gregoire, A.; Le Turnier, P.; Lecompte, A-S.; Lecomte, R.; Lefebvre, M.; Raffi, F.; Boutoille, D.; Morineau, P.H.; Guéry, R.; Chatelus, E.; Dumoussaud, N.; Felten, R.; Luca, F.; Goichot, B.; Schneider, F.; Taquet, M-C.; Groh, M.; Roumier, M.; Neuville, M.; Bachelard, A.; Isernia, V.; Lescure, F-X.; Phung, B-C.; Rachline, A.; Sautereau, A.; Vallois, D.; Bleher, Y.; Boucher, D.; Coudon, C.; Esnault, J.; Guimard, T.; Leautez-Nainville, S.; Merrien, D.; Morrier, M.; Motte-Vincent, P.; Gabeff, R.; Leclerc, H.; Cozic, C.; Decours, R.; Février, R.; Colin, G.; Abgrall, S.; Vignes, D.; Sterpu, R.; Kuellmar, M.; Meersch-Dini, M.; Weiss, R.; Zarbock, A.; Antony, C.; Berger, M.; Brenner, T.; Taube, C.; Herbstreit, F.; Dolff, S.; Konik, M.; Schmidt, K.; Zettler, M.; Witzke, O.; Boell, B.; Garcia Borrega, J.; Koehler, P.; Zander, T.; Dusse, F.; Al-Sawaf, O.; Köhler, P.; Eichenauer, D.; Kochanek, M.; Shimabukuro-Vornhagen, A.; Mellinghoff, S.; Claßen, A.; Heger, J-M.; Meyer-Schwickerath, C.; Liedgens, P.; Heindel, K.; Belkin, A.; Biber, A.; Gilboa, M.; Levy, I.; Litachevsky, V.; Rahav, G.; Finesod Wiedner, A.; Zilberman-Daniels, T.; Oster, Y.; Strahilevitz, J.; Sviri, S.; Baldissera, E.M.; Campochiaro, C.; Cavalli, G.; Dagna, L.; De Luca, G.; Della Torre, E.; Tomelleri, A.; Bernasconi De Luca, D.; Capetti, A.F.; Coen, M.; Cossu, M.V.; Galli, M.; Giacomelli, A.; Gubertini, G.A.; Rusconi, S.; Burastero, G.J.; Digaetano, M.; Guaraldi, G.; Meschiari, M.; Mussini, C.; Puzzolante, C.; Volpi, S.; Aiello, M.; Ariani, A.; Chetta, A.A.; Frizzelli, A.; Ticinesi, A.; Tuttolomondo, D.; Aliberti, S.; Blasi, F.B.; Di Pasquale, M.F.; Misuraca, S.; Pilocane, T.; Simonetta, E.; Aghelmo, A.M.; Angelini, C.; Brunetta, E.; Canonica, G.W.; Ciccarelli, M.; Dal Farra, S.; De Santis, M.; Ferri, S.; Folci, M.; Guidelli, G.M.; Heffler, E.M.; Loiacono, F.; Malipiero, G.; Paoletti, G.; Pedale, R.; Puggioni, F.A.; Racca, F.; Zumbo, A.; Satou, M.; Honda, H.; Lisun, T.; Protsenko, D.; Rubtsov, N.; Beloglazova, I.; Fomina, D.; Lysenko, M.; Serdotetskova, S.; Firstov, V.; Gordeev, I.; Kokorin, I.; Komissarova, K.; Lapochkina, N.; Luchinkina, E.; Malimon, V.; Mamedguseyinova, S.; Polubatonova, K.; Suvorova, N.; Arribas, J.; Borobia Perez, A.M.; de la Calle Prieto, F.; Figueira, J.C.; Motejano, S.R.; Mora-Rillo, M.; Prados, S.C.; Queiruga, P.J.; Fernandez, A.F.; Guerro, B.M.; Bendala Estrada, A.; Caballero, M.A.; Garcia, L.M.E.; García-Martínez, R.; Collado, A.M.; Munoz, G.P.; Torres do Rego, A.; Villalba, G.M.V.; Burrillo, A.; Valerio, M.M.; Gijon, V.P.; Infante, H.S.; Velilla, E.; Machado, M.; Olmedo, M.; Pinilla, B.; Almirante, G.B.; Cañas, R.M.E.; Contreras, M.S.; Cortés, H.A.; Falcó, F.V.; Ferrer, R.R.; Nuvials, C.X.; Ribera, P.E.; Suanzes, D.P.; Rebollo, C.P.; Garcia, A.F.; Soriano, A.; Oliver Caldes, A.; González, C.A.; Cardozo, C.; De la Mora, C.L.; Pena, L.R.; Chamorro, S.; Crespillo-Andujar, C.; Escudero, S.R.; Fortún-Abete, J.; Monge-Maillo, B.; Moreno, Z.A.; Norman, F.; Sanchez, C.M.; Serrano, V.S.; Vizcarra, P. Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med., 2021, 9(5), 522-532.
[http://dx.doi.org/10.1016/S2213-2600(21)00099-0] [PMID: 33676590]

Singh, A.K.; Singh, A.; Singh, R.; Misra, A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab. Syndr., 2021, 15(6), 102329.
[http://dx.doi.org/10.1016/j.dsx.2021.102329] [PMID: 34742052]

Jayk Bernal, A.; Gomes da Silva, M.M.; Musungaie, D.B.; Kovalchuk, E.; Gonzalez, A.; Delos Reyes, V.; Martín-Quirós, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M.L.; Du, J.; Pedley, A.; Assaid, C.; Strizki, J.; Grobler, J.A.; Shamsuddin, H.H.; Tipping, R.; Wan, H.; Paschke, A.; Butterton, J.R.; Johnson, M.G.; De Anda, C. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N. Engl. J. Med., 2022, 386(6), 509-520.
[http://dx.doi.org/10.1056/NEJMoa2116044] [PMID: 34914868]

Mahase, E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ, 2021, 375(2713), n2713.
[http://dx.doi.org/10.1136/bmj.n2713] [PMID: 34750163]

Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]

Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T.F.; Paredes, R.; Sweeney, D.A.; Short, W.R.; Touloumi, G.; Lye, D.C.; Ohmagari, N.; Oh, M.; Ruiz-Palacios, G.M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M.G.; Atmar, R.L.; Creech, C.B.; Lundgren, J.; Babiker, A.G.; Pett, S.; Neaton, J.D.; Burgess, T.H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H.C. Remdesivir for the treatment of Covid-19 — final report. N. Engl. J. Med., 2020, 383(19), 1813-1826.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]

Goldman, J.D.; Lye, D.C.B.; Hui, D.S.; Marks, K.M.; Bruno, R.; Montejano, R.; Spinner, C.D.; Galli, M.; Ahn, M.Y.; Nahass, R.G.; Chen, Y.S.; SenGupta, D.; Hyland, R.H.; Osinusi, A.O.; Cao, H.; Blair, C.; Wei, X.; Gaggar, A.; Brainard, D.M.; Towner, W.J.; Muñoz, J.; Mullane, K.M.; Marty, F.M.; Tashima, K.T.; Diaz, G.; Subramanian, A. Remdesivir for 5 or 10 days in patients with severe Covid-19. N. Engl. J. Med., 2020, 383(19), 1827-1837.
[http://dx.doi.org/10.1056/NEJMoa2015301] [PMID: 32459919]

Spinner, C.D.; Gottlieb, R.L.; Criner, G.J.; Arribas López, J.R.; Cattelan, A.M.; Soriano Viladomiu, A.; Ogbuagu, O.; Malhotra, P.; Mullane, K.M.; Castagna, A.; Chai, L.Y.A.; Roestenberg, M.; Tsang, O.T.Y.; Bernasconi, E.; Le Turnier, P.; Chang, S.C.; SenGupta, D.; Hyland, R.H.; Osinusi, A.O.; Cao, H.; Blair, C.; Wang, H.; Gaggar, A.; Brainard, D.M.; McPhail, M.J.; Bhagani, S.; Ahn, M.Y.; Sanyal, A.J.; Huhn, G.; Marty, F.M. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA, 2020, 324(11), 1048-1057.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]

Zhang, R.; Mylonakis, E. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality. Ann. Intern. Med., 2021, 174(2), JC17.
[http://dx.doi.org/10.7326/ACPJ202102160-017] [PMID: 33524282]

Gottlieb, R.L.; Vaca, C.E.; Paredes, R.; Mera, J.; Webb, B.J.; Perez, G.; Oguchi, G.; Ryan, P.; Nielsen, B.U.; Brown, M.; Hidalgo, A.; Sachdeva, Y.; Mittal, S.; Osiyemi, O.; Skarbinski, J.; Juneja, K.; Hyland, R.H.; Osinusi, A.; Chen, S.; Camus, G.; Abdelghany, M.; Davies, S.; Behenna-Renton, N.; Duff, F.; Marty, F.M.; Katz, M.J.; Ginde, A.A.; Brown, S.M.; Schiffer, J.T.; Hill, J.A. Early remdesivir to prevent progression to severe covid-19 in outpatients. N. Engl. J. Med., 2022, 386(4), 305-315.
[http://dx.doi.org/10.1056/NEJMoa2116846] [PMID: 34937145]

Horby, P.; Mafham, M.; Linsell, L.; Bell, J.L.; Staplin, N.; Emberson, J.R.; Wiselka, M.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Whitehouse, T.; Felton, T.; Williams, J.; Faccenda, J.; Underwood, J.; Baillie, J.K.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Lim, W.S.; Montgomery, A.; Rowan, K.; Tarning, J.; Watson, J.A.; White, N.J.; Juszczak, E.; Haynes, R.; Landray, M.J. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med., 2020, 383(21), 2030-2040.
[http://dx.doi.org/10.1056/NEJMoa2022926] [PMID: 33031652]

Mitjà, O.; Corbacho-Monné, M.; Ubals, M.; Alemany, A.; Suñer, C.; Tebé, C.; Tobias, A.; Peñafiel, J.; Ballana, E.; Pérez, C.A.; Admella, P.; Riera-Martí, N.; Laporte, P.; Mitjà, J.; Clua, M.; Bertran, L.; Sarquella, M.; Gavilán, S.; Ara, J.; Argimon, J.M.; Cuatrecasas, G.; Cañadas, P.; Elizalde-Torrent, A.; Fabregat, R.; Farré, M.; Forcada, A.; Flores-Mateo, G.; López, C.; Muntada, E.; Nadal, N.; Narejos, S.; Nieto, A.; Prat, N.; Puig, J.; Quiñones, C.; Ramírez-Viaplana, F.; Reyes-Urueña, J.; Riveira-Muñoz, E.; Ruiz, L.; Sanz, S.; Sentís, A.; Sierra, A.; Velasco, C.; Vivanco-Hidalgo, R.M.; Zamora, J.; Casabona, J.; Vall-Mayans, M.; González-Beiras, C.; Clotet, B. A Cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N. Engl. J. Med., 2021, 384(5), 417-427.
[http://dx.doi.org/10.1056/NEJMoa2021801] [PMID: 33289973]

Boulware, D.R.; Pullen, M.F.; Bangdiwala, A.S.; Pastick, K.A.; Lofgren, S.M.; Okafor, E.C.; Skipper, C.P.; Nascene, A.A.; Nicol, M.R.; Abassi, M.; Engen, N.W.; Cheng, M.P.; LaBar, D.; Lother, S.A.; MacKenzie, L.J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L.E.; Schwartz, I.S.; McDonald, E.G.; Rajasingham, R.; Lee, T.C.; Hullsiek, K.H. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med., 2020, 383(6), 517-525.
[http://dx.doi.org/10.1056/NEJMoa2016638] [PMID: 32492293]

Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]

Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178, 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]

López-Medina, E.; López, P.; Hurtado, I.C.; Dávalos, D.M.; Ramirez, O.; Martínez, E.; Díazgranados, J.A.; Oñate, J.M.; Chavarriaga, H.; Herrera, S.; Parra, B.; Libreros, G.; Jaramillo, R.; Avendaño, A.C.; Toro, D.F.; Torres, M.; Lesmes, M.C.; Rios, C.A.; Caicedo, I. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19. JAMA, 2021, 325(14), 1426-1435.
[http://dx.doi.org/10.1001/jama.2021.3071] [PMID: 33662102]

Baum, A.; Ajithdoss, D.; Copin, R.; Zhou, A.; Lanza, K.; Negron, N.; Ni, M.; Wei, Y.; Mohammadi, K.; Musser, B.; Atwal, G.S.; Oyejide, A.; Goez-Gazi, Y.; Dutton, J.; Clemmons, E.; Staples, H.M.; Bartley, C.; Klaffke, B.; Alfson, K.; Gazi, M.; Gonzalez, O.; Dick, E., Jr; Carrion, R., Jr; Pessaint, L.; Porto, M.; Cook, A.; Brown, R.; Ali, V.; Greenhouse, J.; Taylor, T.; Andersen, H.; Lewis, M.G.; Stahl, N.; Murphy, A.J.; Yancopoulos, G.D.; Kyratsous, C.A. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science, 2020, 370(6520), 1110-1115.
[http://dx.doi.org/10.1126/science.abe2402] [PMID: 33037066]

Rabaan, A.A.; Tirupathi, R.; Sule, A.A.; Aldali, J.; Mutair, A.A.; Alhumaid, S.; Muzaheed; Gupta, N.; Koritala, T.; Adhikari, R.; Bilal, M.; Dhawan, M.; Tiwari, R.; Mitra, S.; Emran, T.B.; Dhama, K. Viral dynamics and real-time RT-PCR Ct values correlation with disease severity in COVID-19. Diagnostics, 2021, 11(6), 1091.
[http://dx.doi.org/10.3390/diagnostics11061091] [PMID: 34203738]

Garcia-Beltran, W.F.; Lam, E.C.; St Denis, K.; Nitido, A.D.; Garcia, Z.H.; Hauser, B.M.; Feldman, J.; Pavlovic, M.N.; Gregory, D.J.; Poznansky, M.C.; Sigal, A.; Schmidt, A.G.; Iafrate, A.J.; Naranbhai, V.; Balazs, A.B. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, 2021, 184(9), 2372-2383.e9.
[http://dx.doi.org/10.1016/j.cell.2021.03.013] [PMID: 33743213]

Conceicao, C.; Thakur, N.; Human, S.; Kelly, J.T.; Logan, L.; Bialy, D.; Bhat, S.; Stevenson-Leggett, P.; Zagrajek, A.K.; Hollinghurst, P.; Varga, M.; Tsirigoti, C.; Tully, M.; Chiu, C.; Moffat, K.; Silesian, A.P.; Hammond, J.A.; Maier, H.J.; Bickerton, E.; Shelton, H.; Dietrich, I.; Graham, S.C.; Bailey, D. The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. PLoS Biol., 2020, 18(12), e3001016.
[http://dx.doi.org/10.1371/journal.pbio.3001016] [PMID: 33347434]

Krammer, F. SARS-CoV-2 vaccines in development. Nature, 2020, 586(7830), 516-527.
[http://dx.doi.org/10.1038/s41586-020-2798-3] [PMID: 32967006]

Creech, C.B.; Walker, S.C.; Samuels, R.J. SARS-CoV-2 vaccines. JAMA, 2021, 325(13), 1318-1320.
[http://dx.doi.org/10.1001/jama.2021.3199] [PMID: 33635317]

Aydin, S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides, 2015, 72, 4-15.
[http://dx.doi.org/10.1016/j.peptides.2015.04.012] [PMID: 25908411]

Corominas, J.; Garriga, C.; Prenafeta, A.; Moros, A.; Cañete, M.; Barreiro, A.; González-González, L.; Madrenas, L.; Güell, I.; Clotet, B.; Izquierdo-Useros, N.; Raïch-Regué, D.; Gallemí, M.; Blanco, J.; Pradenas, E.; Trinité, B.; Prado, J.G.; Blanch-Lombarte, O.; Pérez-Caballero, R.; Plana, M.; Esteban, I.; Pastor-Quiñones, C.; Núñez-Costa, X.; Taleb, R.A.; McSkimming, P.; Soriano, A.; Nava, J.; Anagua, J.O.; Ramos, R.; Lluch, R.M.; Comes, A.C.; Romero, S.O.; Gomez, X.M.; Sans-Pola, C.; Moltó, J.; Benet, S.; Bailón, L.; Arribas, J.R.; Borobia, A.M.; Parada, J.Q.; Navarro-Pérez, J.; Forner Giner, M.J.; Lucas, R.O.; Jiménez, M.M.V.; Compán, S.O.; Alvarez-Mon, M.; Troncoso, D.; Arana-Arri, E.; Meijide, S.; Imaz-Ayo, N.; García, P.M.; de la Villa Martínez, S.; Fernández, S.R.; Prat, T.; Torroella, È.; Ferrer, L. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Reg. Health Eur., 2023, 28, 100613.
[http://dx.doi.org/10.1016/j.lanepe.2023.100613] [PMID: 37131861]

Ratajczak, P.; Banach, Z.; Kopciuch, D.; Paczkowska, A.; Zaprutko, T.; Krawczyk, J.; Maciuszek-Bartkowska, B.; Kus, K. Tozinameran (Pfizer, BioNTech) and elasomeran (Moderna) efficacy in COVID-19—A systematic review of randomised controlled trial studies. Healthcare, 2023, 11(11), 1532.
[http://dx.doi.org/10.3390/healthcare11111532] [PMID: 37297673]

Knoll, M.D.; Wonodi, C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet, 2021, 397(10269), 72-74.
[http://dx.doi.org/10.1016/S0140-6736(20)32623-4] [PMID: 33306990]

Sah, R.; Shrestha, S.; Mehta, R.; Sah, S.K.; Rabaan, A.A.; Dhama, K.; Rodriguez-Morales, A.J. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal. Travel Med. Infect. Dis., 2021, 40, 101989.
[http://dx.doi.org/10.1016/j.tmaid.2021.101989] [PMID: 33578045]

Sadoff, J.; Gray, G.; Vandebosch, A.; Cárdenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Van Dromme, I.; Spiessens, B.; Vingerhoets, J.; Custers, J.; Scheper, G.; Robb, M.L.; Treanor, J.; Ryser, M.F.; Barouch, D.H.; Swann, E.; Marovich, M.A.; Neuzil, K.M.; Corey, L.; Stoddard, J.; Hardt, K.; Ruiz-Guiñazú, J.; Le Gars, M.; Schuitemaker, H.; Van Hoof, J.; Struyf, F.; Douoguih, M. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N. Engl. J. Med., 2022, 386(9), 847-860.
[http://dx.doi.org/10.1056/NEJMoa2117608] [PMID: 35139271]

Carreño, J.M.; Singh, G.; Tcheou, J.; Srivastava, K.; Gleason, C.; Muramatsu, H.; Desai, P.; Aberg, J.A.; Miller, R.L.; study group, P.A.R.I.S.; Pardi, N.; Simon, V.; Krammer, F. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine, 2022, 40(42), 6114-6124.
[http://dx.doi.org/10.1016/j.vaccine.2022.08.024] [PMID: 36115801]

Mok, C.K.P.; Chen, C.; Zhao, S.; Sun, Y.; Yiu, K.; Chan, T.O.; Lai, H.L.; Lai, K.C.; Lau, K.M.; Ling, K.C.; Chan, K.K.P.; Ng, S.S.; Ko, F.W.; Peiris, M.; Hui, D.S. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study. Lancet Microbe, 2023, 4(6), e418-e430.
[http://dx.doi.org/10.1016/S2666-5247(23)00006-X] [PMID: 37086735]

Sahay, R.R.; Yadav, P.D.; Nandapurkar, A.; Dhawde, R.; Suryawanshi, A.; Patil, D.Y.; Shete, A.M.; Sapkal, G.N.; Kulkarni, M.; Gurav, Y.K.; Deshpande, G.R.; Ghodke, J.S.; Jain, R.; Hawale, R.; Kalele, K.; Yemul, J.; Gawande, P.; Abraham, P. Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months. Hum. Vaccin. Immunother., 2022, 18(7), 2156753.
[http://dx.doi.org/10.1080/21645515.2022.2156753] [PMID: 36576223]

Rydyznski Moderbacher, C.; Kim, C.; Mateus, J.; Plested, J.; Zhu, M.; Cloney-Clark, S.; Weiskopf, D.; Sette, A.; Fries, L.; Glenn, G.; Crotty, S. NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses. J. Clin. Invest., 2022, 132(19), e160898.
[http://dx.doi.org/10.1172/JCI160898] [PMID: 35943810]

Parums, D.V. Editorial: First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants. Med. Sci. Monit., 2022, 28, e936523.
[http://dx.doi.org/10.12659/MSM.936523] [PMID: 35228506]

Jin, P.; Guo, X.; Chen, W.; Ma, S.; Pan, H.; Dai, L.; Du, P.; Wang, L.; Jin, L.; Chen, Y.; Shi, F.; Liu, J.; Xu, X.; Zhang, Y.; Gao, G.F.; Chen, C.; Feng, J.; Li, J.; Zhu, F. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Med., 2022, 19(5), e1003953.
[http://dx.doi.org/10.1371/journal.pmed.1003953] [PMID: 35617368]

Yegorov, S.; Kadyrova, I.; Negmetzhanov, B.; Kolesnikova, Y.; Kolesnichenko, S.; Korshukov, I.; Baiken, Y.; Matkarimov, B.; Miller, M.S.; Hortelano, G.H.; Babenko, D. Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: A prospective cohort study. Sci. Rep., 2022, 12(1), 13207.
[http://dx.doi.org/10.1038/s41598-022-17514-3] [PMID: 35915123]

Sridhar, S.; Joaquin, A.; Bonaparte, M.I.; Bueso, A.; Chabanon, A.L.; Chen, A.; Chicz, R.M.; Diemert, D.; Essink, B.J.; Fu, B.; Grunenberg, N.A.; Janosczyk, H.; Keefer, M.C.; Rivera M, D.M.; Meng, Y.; Michael, N.L.; Munsiff, S.S.; Ogbuagu, O.; Raabe, V.N.; Severance, R.; Rivas, E.; Romanyak, N.; Rouphael, N.G.; Schuerman, L.; Sher, L.D.; Walsh, S.R.; White, J.; von Barbier, D.; de Bruyn, G.; Canter, R.; Grillet, M.H.; Keshtkar-Jahromi, M.; Koutsoukos, M.; Lopez, D.; Masotti, R.; Mendoza, S.; Moreau, C.; Ceregido, M.A.; Ramirez, S.; Said, A.; Tavares-Da-Silva, F.; Shi, J.; Tong, T.; Treanor, J.; Diazgranados, C.A.; Savarino, S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: Interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect. Dis., 2022, 22(5), 636-648.
[http://dx.doi.org/10.1016/S1473-3099(21)00764-7] [PMID: 35090638]

Bravo, L.; Smolenov, I.; Han, H.H.; Li, P.; Hosain, R.; Rockhold, F.; Clemens, S.A.C.; Roa, C., Jr; Borja-Tabora, C.; Quinsaat, A.; Lopez, P.; López-Medina, E.; Brochado, L.; Hernández, E.A.; Reynales, H.; Medina, T.; Velasquez, H.; Toloza, L.B.; Rodriguez, E.J.; de Salazar, D.I.M.; Rodríguez, C.A.; Sprinz, E.; Cerbino-Neto, J.; Luz, K.G.; Schwarzbold, A.V.; Paiva, M.S.; Carlos, J.; Montellano, M.E.B.; de Los Reyes, M.R.A.; Yu, C.Y.; Alberto, E.R.; Panaligan, M.M.; Salvani-Bautista, M.; Buntinx, E.; Hites, M.; Martinot, J.B.; Bhorat, Q.E.; Badat, A.; Baccarini, C.; Hu, B.; Jurgens, J.; Engelbrecht, J.; Ambrosino, D.; Richmond, P.; Siber, G.; Liang, J.; Clemens, R. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: A phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 2022, 399(10323), 461-472.
[http://dx.doi.org/10.1016/S0140-6736(22)00055-1] [PMID: 35065705]

Abdoli, A.; Aalizadeh, R.; Aminianfar, H.; Kianmehr, Z.; Teimoori, A.; Azimi, E.; Emamipour, N.; Eghtedardoost, M.; Siavashi, V.; Jamshidi, H.; Hosseinpour, M.; Taqavian, M.; Jalili, H. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study. Rev. Med. Virol., 2022, 32(3), e2305.
[http://dx.doi.org/10.1002/rmv.2305] [PMID: 34699647]

Más-Bermejo, P.I.; Dickinson-Meneses, F.O.; Almenares-Rodríguez, K.; Sánchez-Valdés, L.; Guinovart-Díaz, R.; Vidal-Ledo, M.; Galbán-García, E.; Olivera-Nodarse, Y.; Morgado-Vega, I.; Dueñas-Carrera, S.; Pujol, M.; Hernández-Bernal, F.; Limonta-Fernández, M.; Guillén-Nieto, G.; Muzio-González, V.L.; Ayala-Ávila, M. Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study. Lancet Regional Health - Americas, 2022, 16, 100366.
[http://dx.doi.org/10.1016/j.lana.2022.100366] [PMID: 36185968]

Larkin, H.D. Novavax COVID-19 vaccine booster authorized. JAMA, 2022, 328(21), 2101.
[http://dx.doi.org/10.1001/jama.2022.20028] [PMID: 36472611]

Jaggaiahgari, S.; Munigela, A.; Mitnala, S.; Gujjarlapudi, D.; Simhadri, V.; D, N.R. Heterologous booster dose with CORBEVAX following primary vaccination with COVISHIELD Enhances protection against SARS-CoV-2. Vaccines, 2022, 10(12), 2146.
[http://dx.doi.org/10.3390/vaccines10122146] [PMID: 36560556]

Song, J.Y.; Choi, W.S.; Heo, J.Y.; Lee, J.S.; Jung, D.S.; Kim, S.W.; Park, K.H.; Eom, J.S.; Jeong, S.J.; Lee, J.; Kwon, K.T.; Choi, H.J.; Sohn, J.W.; Kim, Y.K.; Noh, J.Y.; Kim, W.J.; Roman, F.; Ceregido, M.A.; Solmi, F.; Philippot, A.; Walls, A.C.; Carter, L.; Veesler, D.; King, N.P.; Kim, H.; Ryu, J.H.; Lee, S.J.; Park, Y.W.; Park, H.K.; Cheong, H.J. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. EClinical Med., 2022, 51, 101569.
[http://dx.doi.org/10.1016/j.eclinm.2022.101569] [PMID: 35879941]

Nguyen, T.P.; Do, Q.; Phan, L.T.; Dinh, D.V.; Khong, H.; Hoang, L.V.; Nguyen, T.V.; Pham, H.N.; Chu, M.V.; Nguyen, T.T.; Pham, Q.D.; Le, T.M.; Trang, T.N.T.; Dinh, T.T.; Vo, T.V.; Vu, T.T.; Nguyen, Q.B.P.; Phan, V.T.; Nguyen, L.V.; Nguyen, G.T.; Tran, P.M.; Nghiem, T.D.; Tran, T.V.; Nguyen, T.G.; Tran, T.Q.; Nguyen, L.T.; Do, A.T.; Nguyen, D.D.; Ho, S.A.; Nguyen, V.T.; Pham, D.T.; Tran, H.B.; Vu, S.T.; Hoang, S.X.; Do, T.M.; Ngoc, H.V.; Nguyen, X.T.; Le, G.Q.; Tran, T.; Cao, T.M.; Dao, H.M.; Nguyen, T.T.T.; Doan, U.Y.; Le, V.T.T.; Tran, L.P.; Nguyen, N.M.; Nguyen, N.T.; Pham, H.T.T.; Nguyen, Q.H.; Nguyen, H.T.; Nguyen, H.L.K.; Tran, V.T.; Tran, M.T.N.; Nguyen, T.T.T.; Ha, P.T.; Huynh, H.T.; Nguyen, K.D.; Thuan, U.T.; Doan, C.C.; Do, S.M. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. Lancet Regional Health - Western Pacific, 2022, 24, 100474.
[http://dx.doi.org/10.1016/j.lanwpc.2022.100474] [PMID: 35602004]

Dolgin, E. CureVac COVID vaccine let-down spotlights mRNA design challenges. Nature, 2021, 594(7864), 483.
[http://dx.doi.org/10.1038/d41586-021-01661-0] [PMID: 34145413]

Hager, K.J.; Pérez Marc, G.; Gobeil, P.; Diaz, R.S.; Heizer, G.; Llapur, C.; Makarkov, A.I.; Vasconcellos, E.; Pillet, S.; Riera, F.; Saxena, P.; Geller Wolff, P.; Bhutada, K.; Wallace, G.; Aazami, H.; Jones, C.E.; Polack, F.P.; Ferrara, L.; Atkins, J.; Boulay, I.; Dhaliwall, J.; Charland, N.; Couture, M.M.J.; Jiang-Wright, J.; Landry, N.; Lapointe, S.; Lorin, A.; Mahmood, A.; Moulton, L.H.; Pahmer, E.; Parent, J.; Séguin, A.; Tran, L.; Breuer, T.; Ceregido, M.A.; Koutsoukos, M.; Roman, F.; Namba, J.; D’Aoust, M.A.; Trepanier, S.; Kimura, Y.; Ward, B.J. Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N. Engl. J. Med., 2022, 386(22), 2084-2096.
[http://dx.doi.org/10.1056/NEJMoa2201300] [PMID: 35507508]

Pilapitiya, D.; Wheatley, A.K.; Tan, H.X. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine, 2023, 92, 104585.
[http://dx.doi.org/10.1016/j.ebiom.2023.104585] [PMID: 37146404]

Wang, C.Y.; Hwang, K.P.; Kuo, H.K.; Peng, W.J.; Shen, Y.H.; Kuo, B.S.; Huang, J.H.; Liu, H.; Ho, Y.H.; Lin, F.; Ding, S.; Liu, Z.; Wu, H.T.; Huang, C.T.; Lee, Y.J.; Liu, M.C.; Yang, Y.C.; Lu, P.L.; Tsai, H.C.; Lee, C.H.; Shi, Z.Y.; Liu, C.E.; Liao, C.H.; Chang, F.Y.; Chen, H.C.; Wang, F.D.; Hou, K.L.; Cheng, J.; Wang, M.S.; Yang, Y.T.; Chiu, H.C.; Jiang, M.H.; Shih, H.Y.; Shen, H.Y.; Chang, P.Y.; Lan, Y.R.; Chen, C.T.; Lin, Y.L.; Liang, J.J.; Liao, C.C.; Chou, Y.C.; Morris, M.K.; Hanson, C.V.; Guirakhoo, F.; Hellerstein, M.; Yu, H.J.; King, C.C.; Kemp, T.; Heppner, D.G.; Monath, T.P. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J. Clin. Invest., 2022, 132(10), e157707.
[http://dx.doi.org/10.1172/JCI157707] [PMID: 35316221]

Hashimoto, M.; Nagata, N.; Homma, T.; Maeda, H.; Dohi, K.; Seki, N.M.; Yoshihara, K.; Iwata-Yoshikawa, N.; Shiwa-Sudo, N.; Sakai, Y.; Shirakura, M.; Kishida, N.; Arita, T.; Suzuki, Y.; Watanabe, S.; Asanuma, H.; Sonoyama, T.; Suzuki, T.; Omoto, S.; Hasegawa, H. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Vaccine, 2022, 40(31), 4231-4241.
[http://dx.doi.org/10.1016/j.vaccine.2022.05.081] [PMID: 35691872]

Janssen, Y.F.; Feitsma, E.A.; Boersma, H.H.; Alleva, D.G.; Lancaster, T.M.; Sathiyaseelan, T.; Murikipudi, S.; Delpero, A.R.; Scully, M.M.; Ragupathy, R.; Kotha, S.; Haworth, J.R.; Shah, N.J.; Rao, V.; Nagre, S.; Ronca, S.E.; Green, F.M.; Aminetzah, A.; Sollie, F.; Kruijff, S.; Brom, M.; van Dam, G.M.; Zion, T.C. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine, 2022, 40(9), 1253-1260.
[http://dx.doi.org/10.1016/j.vaccine.2022.01.043] [PMID: 35115195]

Torales, J.; Cuenca-Torres, O.; Barrios, L.; Armoa-Garcia, L.; Estigarribia, G.; Sanabria, G.; Lin, M.Y.; Antonio Estrada, J.; Estephan, L.; Cheng, H.Y.; Chen, C.; Janssen, R.; Lien, C.E. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. Vaccine, 2023, 41(1), 109-118.
[http://dx.doi.org/10.1016/j.vaccine.2022.10.030] [PMID: 36404171]

Lazarus, R.; Taucher, C.; Brown, C.; Čorbic Ramljak, I.; Danon, L.; Dubischar, K.; Duncan, C.J.A.; Eder-Lingelbach, S.; Faust, S.N.; Green, C.; Gokani, K.; Hochreiter, R.; Wright, J.K.; Kwon, D.; Middleditch, A.; Munro, A.P.S.; Naker, K.; Penciu, F.; Price, D.; Querton, B.; Riaz, T.; Ross-Russell, A.; Sanchez-Gonzalez, A.; Wardle, H.; Warren, S.; Finn, A. Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. J. Infect., 2022, 85(3), 306-317.
[http://dx.doi.org/10.1016/j.jinf.2022.06.009] [PMID: 35718205]

Banihashemi, S.R.; Es-haghi, A.; Fallah Mehrabadi, M.H.; Nofeli, M.; Mokarram, A.R.; Ranjbar, A.; Salman, M.; Hajimoradi, M.; Razaz, S.H.; Taghdiri, M.; Bagheri, M.; Dadar, M.; Hassan, Z.M.; Eslampanah, M.; Salehi, Z.; Lotfi, M.; Khorasani, A.; Rahmani, F. Safety and efficacy of combined intramuscular/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: A preclinical study in several animal models. Front. Immunol., 2022, 13, 836745.
[http://dx.doi.org/10.3389/fimmu.2022.836745] [PMID: 35693788]

Hannawi, S.; Saifeldin, L.; Abuquta, A.; Alamadi, A.; Mahmoud, S.A.; Hassan, A.; Liu, D.; Yan, L.; Xie, L. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial. EBioMedicine, 2023, 87, 104386.
[http://dx.doi.org/10.1016/j.ebiom.2022.104386] [PMID: 36470077]

Wang, J.; Mai, X.; He, Y.; Zhu, C.; Zhou, D. IgG1-dominant antibody response induced by recombinant trimeric SARS-CoV-2 spike protein with PIKA adjuvant. Vaccines, 2023, 11(4), 827.
[http://dx.doi.org/10.3390/vaccines11040827] [PMID: 37112739]

Low, J.G.; de Alwis, R.; Chen, S.; Kalimuddin, S.; Leong, Y.S.; Mah, T.K.L.; Yuen, N.; Tan, H.C.; Zhang, S.L.; Sim, J.X.Y.; Chan, Y.F.Z.; Syenina, A.; Yee, J.X.; Ong, E.Z.; Sekulovich, R.; Sullivan, B.B.; Lindert, K.; Sullivan, S.M.; Chivukula, P.; Hughes, S.G.; Ooi, E.E. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines, 2022, 7(1), 161.
[http://dx.doi.org/10.1038/s41541-022-00590-x] [PMID: 36513697]

Tabarsi, P.; Anjidani, N.; Shahpari, R.; Roshanzamir, K.; Fallah, N.; Andre, G.; Petrovsky, N.; Barati, S. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. Immunology, 2022, 167(3), 340-353.
[http://dx.doi.org/10.1111/imm.13540] [PMID: 35758850]

Sunagar, R.; Prasad, S.D.; Ella, R.; Vadrevu, K.M. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front. Immunol., 2022, 13, 1063679.
[http://dx.doi.org/10.3389/fimmu.2022.1063679] [PMID: 36569867]

Kaabi, N.A.; Yang, Y.K.; Du, L.F.; Xu, K.; Shao, S.; Liang, Y.; Kang, Y.; Su, J.G.; Zhang, J.; Yang, T.; Hussein, S.; ElDein, M.S.; Yang, S.S.; Lei, W.; Gao, X.J.; Jiang, Z.; Cong, X.; Tan, Y.; Wang, H.; Li, M.; Mekki, H.M.; Zaher, W.; Mahmoud, S.; Zhang, X.; Qu, C.; Liu, D.Y.; Zhang, J.; Yang, M.; Eltantawy, I.; Hou, J.W.; Lei, Z.H.; Xiao, P.; Wang, Z.N.; Yin, J.L.; Mao, X.Y.; Zhang, J.; Qu, L.; Zhang, Y.T.; Yang, X.M.; Wu, G.; Li, Q.M. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat. Commun., 2022, 13(1), 3654.
[http://dx.doi.org/10.1038/s41467-022-31379-0] [PMID: 35760812]

Zhang, Z.; He, Q.; Zhao, W.; Li, Y.; Yang, J.; Hu, Z.; Chen, X.; Peng, H.; Fu, Y.X.; Chen, L.; Lu, L. A heterologous V-01 or variant-matched bivalent V-01D-351 booster following primary series of inactivated vaccine enhances the neutralizing capacity against SARS-CoV-2 delta and omicron strains. J. Clin. Med., 2022, 11(14), 4164.
[http://dx.doi.org/10.3390/jcm11144164] [PMID: 35887928]

Pajon, R.; Doria-Rose, N.A.; Shen, X.; Schmidt, S.D.; O’Dell, S.; McDanal, C.; Feng, W.; Tong, J.; Eaton, A.; Maglinao, M.; Tang, H.; Manning, K.E.; Edara, V.V.; Lai, L.; Ellis, M.; Moore, K.M.; Floyd, K.; Foster, S.L.; Posavad, C.M.; Atmar, R.L.; Lyke, K.E.; Zhou, T.; Wang, L.; Zhang, Y.; Gaudinski, M.R.; Black, W.P.; Gordon, I.; Guech, M.; Ledgerwood, J.E.; Misasi, J.N.; Widge, A.; Sullivan, N.J.; Roberts, P.C.; Beigel, J.H.; Korber, B.; Baden, L.R.; El Sahly, H.; Chalkias, S.; Zhou, H.; Feng, J.; Girard, B.; Das, R.; Aunins, A.; Edwards, D.K.; Suthar, M.S.; Mascola, J.R.; Montefiori, D.C. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med., 2022, 386(11), 1088-1091.
[http://dx.doi.org/10.1056/NEJMc2119912] [PMID: 35081298]

Tan, NH; Geers, D; Sablerolles, RSG; Rietdijk, WJR; Goorhuis, A; Postma, DF; Visser, LG; Bogers, S; van Dijk, LLA; Gommers, L; van Leeuwen, LPM; Boerma, A; Nijhof, SH; van Dort, KA; Koopmans, MPG; Dalm, VASH; Lafeber, M; Kootstra, NA; Huckriede, ALW; van Baarle, D; Zaeck, LM Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): Results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect Dis, 2023, 23(8), 901-913.
[http://dx.doi.org/10.1016/S1473-3099(23)00140-8]